Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections
Sajad NajafiStudent Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranShing Cheng TanUKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaShahin AghamiriStudent Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranPourya RaeeDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranZahra EbrahimiStudent Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranZahra Kargar JahromiCentral Research Laboratory, Jahrom University of Medical Sciences, Jahrom, IranYazdan RahmatiDepartment of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranJavid Sadri NahandInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, IranAhmad PiroozmandAutoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, IranVahid JajarmiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: [email protected]Hamed MirzaeiStudent Research Committee, Kashan University of Medical Sciences, Kashan, Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: [email protected]
2022en
ABI
Аннотация
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0